Get the Stockscreener App
8.82
2.20%
0.19
After Hours:
8.82
Alumis Inc stock is traded at $8.82, with a volume of 394.80K.
It is up +2.20% in the last 24 hours and down -8.51% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$8.63
Open:
$8.51
24h Volume:
394.80K
Relative Volume:
2.55
Market Cap:
$479.87M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.13%
1M Performance:
-8.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.29
$8.92
1-Week Range:
$8.25
$9.20
52-Week Range:
$7.66
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
8.82 | 479.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor - Yahoo! Voices
Alumis (NASDAQ:ALMS) Given "Buy" Rating at HC Wainwright - MarketBeat
Alumis reports promising Phase 1 trial results for MS drug - Investing.com
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - The Bakersfield Californian
Alumis Reports Breakthrough Clinical Data: TYK2 Drug Shows Strong Brain Penetration in Phase 1 Trial - StockTitan
Charles Schwab Investment Management Inc. Takes $1.16 Million Position in Alumis Inc. (NASDAQ:ALMS) - Defense World
Charles Schwab Investment Management Inc. Invests $1.16 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To Expire on December 25th - Defense World
Alumis Inc.'s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th - MarketBeat
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Pre-market Movers: LOOP, RPTX, CADL, INO, ISPC… - RTTNews
(ALMS) Technical Data - Stock Traders Daily
Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Samsara BioCapital LLC Acquires Shares of 3,266,498 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Quantisnow
How the (ALMS) price action is used to our Advantage - Stock Traders Daily
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Ally Bridge Group NY LLC Cuts Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis: A Best-In-Class TYK2 Inhibitor (NASDAQ:ALMS) - Seeking Alpha
Alumis updates clinical trial dates for lupus study By Investing.com - Investing.com Australia
Alumis updates clinical trial dates for lupus study - Investing.com
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat
HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $26.00 - Defense World
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis' ESK-001 Shows Promise in Lupus Treatment, New Clinical Data Revealed at ACR 2024 | ALMS Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Towerview LLC Buys 70,000 Shares of Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Price Target Lowered to $26.00 at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Reports 93% Success in Psoriasis Trial, Q3 Loss Widens to $93.1M | ALMS Stock News - StockTitan
Telsey Advisory Group Predicts Reduced Earnings for FIGS - Defense World
Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50 - MarketBeat
U.S. Energy (NASDAQ:USEG) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chase (NYSE:CCF) Coverage Initiated by Analysts at StockNews.com - Defense World
CGI Inc. (NYSE:GIB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug - MSN
Uveitis Clinical Trials 2024: FDA Approvals, Medication, - openPR
How to Take Advantage of moves in (ALMS) - Stock Traders Daily
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Net Present Value Model: Alumis Inc’s ESK-001 - GlobalData
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Alumis Inc Stock (ALMS) Financials Data
There is no financial data for Alumis Inc (ALMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Capital Management V, | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Tananbaum James B. | Director |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):